In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in a Neutropenic Mouse Bloodstream Infection Model
Abstract
:1. Introduction
2. Materials and Methods
2.1. Isolates
2.2. Lethality Experiments
2.3. Fungal Tissue Burden Experiments
2.4. Histopathology
3. Results
3.1. Lethality Experiments
3.1.1. South Asian Clade
3.1.2. East Asian Clade
3.1.3. South African Clade
3.1.4. South American Clade
3.2. Fungal Burden Experiments
3.2.1. Kidneys
3.2.2. Heart
3.2.3. Brain
4. Histopathology
5. Discussion
6. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- World Health Organization. WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action; World Health Organization: Geneva, Switzerland, 2022.
- Lockhart, S.R.; Etienne, K.A.; Vallabhaneni, S.; Farooqi, J.; Chowdhary, A.; Govender, N.P.; Colombo, A.L.; Calvo, B.; Cuomo, C.A.; Desjardins, C.A.; et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin. Infect. Dis. 2017, 64, 134–140. [Google Scholar] [CrossRef] [PubMed]
- Osei Sekyere, J. Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. MicrobiologyOpen 2018, 7, e578. [Google Scholar] [CrossRef] [PubMed]
- Pappas, P.G.; Kauffman, C.A.; Andes, D.R.; Clancy, C.J.; Marr, K.A.; Ostrosky-Zeichner, L.; Reboli, A.C.; Schuster, M.G.; Vazquez, J.A.; Walsh, T.J.; et al. Clinical practice guideline for the management of candidiasis: Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2016, 62, e1–e50. [Google Scholar] [CrossRef] [PubMed]
- CDC. Available online: https://www.cdc.gov/candida-auris/hcp/laboratories/antifungal-susceptibility-testing.html (accessed on 1 July 2024).
- Bellmann, R.; Smuszkiewicz, P. Pharmacokinetics of antifungal drugs: Practical implications for optimized treatment of patients. Infection 2017, 45, 737–779. [Google Scholar] [CrossRef]
- Emri, T.; Majoros, L.; Tóth, V.; Pócsi, I. Echinocandins: Production and applications. Appl. Microbiol. Biotechnol. 2013, 97, 3267–3284. [Google Scholar] [CrossRef]
- Yamada, N.; Kumada, K.; Kishino, S.; Mochizuki, N.; Ohno, K.; Ogura, S. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J. Infect. Chemother. 2011, 17, 731–734. [Google Scholar] [CrossRef]
- Shields, R.K.; Nguyen, M.H.; Press, E.G.; Clancy, C.J. Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob. Agents Chemother. 2014, 58, 7601–7605. [Google Scholar] [CrossRef]
- Grau, S.; Luque, S.; Campillo, N.; Samsó, E.; Rodríguez, U.; García-Bernedo, C.A.; Salas, E.; Sharma, R.; Hope, W.W.; Roberts, J.A. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J. Antimicrob. Chemother. 2015, 70, 2854–2861. [Google Scholar] [CrossRef]
- Lempers, V.J.; Schouten, J.A.; Hunfeld, N.G.; Colbers, A.; van Leeuwen, H.J.; Burger, D.M.; Verweij, P.E.; Pickkers, P.; Brüggemann, R.J. Altered micafungin pharmacokinetics in intensive care unit patients. Antimicrob. Agents Chemother. 2015, 59, 4403–4409. [Google Scholar] [CrossRef]
- Moriyama, B.; Ditullio, M.; Wilson, E.; Henning, S.A.; Penzak, S.R.; Danner, R.L.; Pennick, G.; Rinaldi, M.G.; Zelazny, A.M.; Gea-Banacloche, J.; et al. Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema. Antimicrob. Agents Chemother. 2011, 55, 2478–2480. [Google Scholar] [CrossRef]
- Syed, Y.Y. Rezafungin: First Approval. Drugs 2023, 83, 833–840. [Google Scholar] [CrossRef] [PubMed]
- Tóth, Z.; Forgács, L.; Locke, J.B.; Kardos, G.; Nagy, F.; Kovács, R.; Szekely, A.; Borman, A.M.; Majoros, L. In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae. J. Antimicrob. Chemother. 2019, 74, 3505–3510. [Google Scholar] [CrossRef]
- Kovács, R.; Tóth, Z.; Locke, J.B.; Forgács, L.; Kardos, G.; Nagy, F.; Borman, A.M.; Majoros, L. Comparison of in vitro killing activity of rezafungin, anidulafungin, caspofungin, and micafungin against four Candida auris clades in RPMI-1640 in the absence and presence of human serum. Microorganisms 2021, 9, 863. [Google Scholar] [CrossRef] [PubMed]
- Forgács, L.; Borman, A.M.; Prépost, E.; Tóth, Z.; Kardos, G.; Kovács, R.; Szekely, A.; Nagy, F.; Kovacs, I.; Majoros, L. Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine model. Emerg. Microbes Infect. 2020, 9, 1160–1169. [Google Scholar] [CrossRef] [PubMed]
- Adnan, A.; Borman, A.M.; Tóth, Z.; Forgács, L.; Kovács, R.; Balázsi, D.; Balázs, B.; Udvarhelyi, G.; Kardos, G.; Majoros, L. In vitro killing activities of anidulafungin and micafungin with and without nikkomycin Z against four Candida auris clades. Pharmaceutics 2023, 15, 1365. [Google Scholar] [CrossRef]
- Borman, A.M.; Szekely, A.; Johnson, E.M. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen, Candida auris and other key pathogenic Candida species. mSphere 2016, 18, e00189-16. [Google Scholar] [CrossRef]
- Szekely, A.; Borman, A.M.; Johnson, E.M. Candida auris isolates of the Southern Asian and South African lineages exhibit different phenotypic and antifungal susceptibility profiles in vitro. J. Clin. Microbiol. 2019, 57, e02055-18. [Google Scholar] [CrossRef]
- Borman, A.M.; Szekely, A.; Johnson, E.M. Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins. Med. Mycol. 2017, 55, 563–567. [Google Scholar] [CrossRef]
- Alexander, B.D.; Procop, G.W.; Dufresne, P.; Fuller, J.; Ghannoum, M.A.; Hanson, K.E.; Holliday, D.; Holliday, M.N.; Kovanda, L.; Lockhart, S.R.; et al. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 4th ed.; M27 Ed4; Clinical and Laboratory Standards Institute, CLSI: Wayne, PA, USA, 2017. [Google Scholar]
- Alexander, B.D.; Procop, G.W.; Fuller, J.; Fothergill, A.W.; Ghannoum, M.A.; Hanson, K.E.; Holliday, D.; Holliday, M.N.; Ostrosky-Zeichner, L.; Schuetz, A.N.; et al. Performance Standards for Antifungal Susceptibility Testing of Yeasts, 3rd ed.; CLSI Supplement M27M44S; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2022. [Google Scholar]
- Forgács, L.; Borman, A.M.; Kovács, R.; Balázsi, D.; Tóth, Z.; Balázs, B.; Chun-Ju, C.; Kardos, G.; Kovacs, I.; Majoros, L. In vivo efficacy of amphotericin B against four Candida auris clades. J. Fungi 2022, 8, 499. [Google Scholar] [CrossRef]
- Hager, C.L.; Larkin, E.L.; Long, L.A.; Ghannoum, M.A. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J. Antimicrob. Chemother. 2018, 73, 2085–2088. [Google Scholar] [CrossRef]
- Wiederhold, N.P.; Najvar, L.K.; Bocanegra, R.; Kirkpatrick, W.R.; Patterson, T.F. Comparison of anidulafungin’s and fluconazole’s in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis. Clin. Microbiol. Infect. 2012, 18, E20–E23. [Google Scholar] [CrossRef] [PubMed]
- Prépost, E.; Tóth, Z.; Perlin, D.S.; Gesztelyi, R.; Kardos, G.; Kovács, R.; Nagy, F.; Forgács, L.; Majoros, L. Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis. Infect. Drug Resist. 2019, 12, 805–1814. [Google Scholar] [CrossRef] [PubMed]
- Lepak, A.J.; Zhao, M.; Berkow, E.L.; Lockhart, S.R.; Andes, D.R. Pharmacodynamic optimization for treatment of invasive Candida auris infection. Antimicrob. Agents Chemother. 2017, 61, e00791-17. [Google Scholar] [CrossRef] [PubMed]
- Lepak, A.J.; Zhao, M.; Andes, D.R. Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model. Antimicrob. Agents Chemother. 2018, 62, e01572-18. [Google Scholar] [CrossRef]
- Helleberg, M.; Jørgensen, K.M.; Hare, R.K.; Datcu, R.; Chowdhary, A.; Arendrup, M.C. Rezafungin in vitro activity against contemporary Nordic clinical Candida isolates and Candida auris determined by the EUCAST reference method. Antimicrob. Agents Chemother. 2020, 64, e02438-19. [Google Scholar] [CrossRef] [PubMed]
- Berkow, E.L.; Lockhart, S.R. Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris. Diagn. Microbiol. Infect. Dis. 2018, 90, 196–197. [Google Scholar] [CrossRef]
- Bretagne, S.; Desnos-Ollivier, M.; Sitbon, K.; Lortholary, O.; Che, D.; Dromer, F.; Participants of the YEASTS. No Impact of fluconazole to echinocandins replacement as first-line therapy on the epidemiology of yeast fungemia (Hospital-Driven Active Surveillance, 2004–2017, Paris, France). Front. Med. 2021, 8, 641965. [Google Scholar]
- Betts, R.F.; Nucci, M.; Talwar, D.; Gareca, M.; Queiroz-Telles, F.; Bedimo, R.J.; Herbrecht, R.; Ruiz-Palacios, G.; Young, J.A.; Baddley, J.W.; et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin. Infect. Dis. 2009, 48, 1676–1684. [Google Scholar]
- Pappas, P.G.; Rotstein, C.M.; Betts, R.F.; Nucci, M.; Talwar, D.; De Waele, J.J.; Vazquez, J.A.; Dupont, B.F.; Horn, D.L.; Ostrosky-Zeichner, L.; et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 2007, 45, 883–893. [Google Scholar] [CrossRef]
- Sandison, T.; Ong, V.; Lee, J.; Thye, D. Safety and Pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob. Agents Chemother. 2017, 61, e01627-16. [Google Scholar] [CrossRef]
- Thompson, G.R., III; Soriano, A.; Honore, P.M.; Bassetti, M.; Cornely, O.A.; Kollef, M.; Kullberg, B.J.; Pullman, J.; Hites, M.; Fortún, J.; et al. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: Pooled data from two prospective randomised controlled trials. Lancet Infect. Dis. 2024, 24, 319–328. [Google Scholar] [PubMed]
- Ong, V.; James, K.D.; Smith, S.; Krishnan, B.R. Pharmacokinetics of the novel echinocandin CD101 in multiple animal species. Antimicrob. Agents Chemother. 2017, 61, e01626-16. [Google Scholar] [CrossRef] [PubMed]
- Spellberg, B.; Ibrahim, A.S.; Edwards, J.E., Jr.; Filler, S.G. Mice with disseminated candidiasis die of progressive sepsis. J. Infect. Dis. 2005, 192, 336–343. [Google Scholar] [CrossRef] [PubMed]
- Chowdhary, A.; Tarai, B.; Singh, A.; Sharma, A. Multidrug-resistant Candida auris infections in critically ill Coronavirus disease patients, India, April–July 2020. Emerg. Infect. Dis. 2020, 26, 2694–2696. [Google Scholar] [CrossRef] [PubMed]
- Villanueva-Lozano, H.; Treviño-Rangel, R.J.; González, G.M.; Ramírez-Elizondo, M.T.; Lara-Medrano, R.; Aleman-Bocanegra, M.C.; Guajardo-Lara, C.E.; Gaona-Chávez, N.; Castilleja-Leal, F.; Torre-Amione, G.; et al. Outbreak of Candida auris infection in a COVID-19 hospital in Mexico. Clin. Microbiol. Infect. 2021, 27, 813–816. [Google Scholar] [CrossRef]
- Roepcke, S.; Passarell, J.; Walker, H.; Flanagan, S. Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis. Antimicrob. Agents Chemother. 2023, 67, e0091623. [Google Scholar] [CrossRef]
Isolates Number | Clade | Body Site | Aggregation | MIC Values (mg/L) | |||
---|---|---|---|---|---|---|---|
REZA | ANF | CAS | MCF | ||||
27 (NCPF 8991) | South Asian | Pleural fluid | − | 0.12 | 0.12 | 0.5 | 0.25 |
196 | South Asian | Blood | − | 0.25 | 0.12 | 0.5 | 0.25 |
12372 (CBS 12372) | East Asian | Blood | + | 0.06 | 0.03 | 0.12 | 0.03 |
12373 (CBS 12373) | East Asian | Blood | + | 0.12 | 0.06 | 0.25 | 0.06 |
2 (NCPF 8977) | South African | Cerebrospinal fluid | + | 0.12 | 0.03 | 0.5 | 0.25 |
204 | South African | Tracheostomy | + | 0.06 | 0.03 | 0.25 | 0.12–0.25 |
I-24 | South American (Israel) | Blood | − | 0.25 | 0.06 | 0.25 | 0.12 |
I-156 | South American (Israel) | Blood | − | 0.25 | 0.06 | 0.5 | 0.12 |
13108 (CDC B-13108) | South American (Colombia) | Hospital environment | − | 0.12 | 0.06 | 0.25 | 0.12 |
13112 (CDC B-13112) | South American (Colombia) | Hospital environment | − | 0.25 | 0.12 | 0.25 | 0.12 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Balázsi, D.; Tóth, Z.; Locke, J.B.; Borman, A.M.; Forgács, L.; Balla, N.; Kovács, F.; Kovács, R.; Amano, C.; Baran, T.I.; et al. In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in a Neutropenic Mouse Bloodstream Infection Model. J. Fungi 2024, 10, 617. https://doi.org/10.3390/jof10090617
Balázsi D, Tóth Z, Locke JB, Borman AM, Forgács L, Balla N, Kovács F, Kovács R, Amano C, Baran TI, et al. In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in a Neutropenic Mouse Bloodstream Infection Model. Journal of Fungi. 2024; 10(9):617. https://doi.org/10.3390/jof10090617
Chicago/Turabian StyleBalázsi, Dávid, Zoltán Tóth, Jeffrey B. Locke, Andrew M. Borman, Lajos Forgács, Noémi Balla, Fruzsina Kovács, Renátó Kovács, Chiaki Amano, Tugba Ilay Baran, and et al. 2024. "In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in a Neutropenic Mouse Bloodstream Infection Model" Journal of Fungi 10, no. 9: 617. https://doi.org/10.3390/jof10090617